Yes, Novo Nordisk allowed a Canadian patent related to semaglutide to lapse, after missing a $450 maintenance fee — but this wasn’t a billion-dollar blunder. In fact, the key...
- +1 647-745-1684
- info@mattixgroup.com
- Mon - Fri 08.00 - 18.00
